AstraZeneca PLC Qtrilmet recommended for approval in EU by CHMP

Date : 09/23/2019 @ 6:01AM
Source : UK Regulatory (RNS & others)
Stock : Astrazeneca Plc (AZN)
Quote : 7222.0  -36.0 (-0.50%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca PLC Qtrilmet recommended for approval in EU by CHMP

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Astrazeneca Charts.

TIDMAZN

RNS Number : 2444N

AstraZeneca PLC

23 September 2019

23 September 2019 07:00 BST

Qtrilmet recommended for approval in EU by

CHMP for the treatment of type-2 diabetes

AstraZeneca today announced that Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets have been recommended for marketing authorisation in the European Union for the treatment of adults with type-2 diabetes (T2D).

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with inadequately-controlled T2D. The primary endpoint in these trials was mean change from baseline in HbA1c (average blood glucose levels) at week 24 or 52.

Across the trials, the combination of Forxiga, Onglyza and metformin was superior in reducing HbA1c versus Forxiga combined with metformin, Onglyza combined with metformin, or glimepiride combined with metformin. The combination of Forxiga, Onglyza and metformin with or without sulphonylurea (SU) was non-inferior to the combined use of insulin and metformin with or without SU in reducing HbA1c.

The safety results of the individual medicines in these trials were consistent with their known profile.

The CHMP recommended the marketing authorisation for Qtrilmet to improve glycaemic control when metformin with or without SU and either saxagliptin or dapagliflozin does not provide adequate glycaemic control, or when T2D patients are already being treated with metformin, saxagliptin and dapagliflozin.

Qtrilmetis approved in the US under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with T2D.

About Qtrilmet

Qtrilmetis a once-daily, oral medicine comprised of the selective sodium--glucose co-transporter 2 (SGLT2) inhibitor Forxiga, the dipeptidyl peptidase--4 (DPP--4) inhibitor Onglyza and metformin hydrochloride extended release indicated as treatment in adults with T2D.

About AstraZeneca in CVRM

Cardiovascular, Renal & Metabolism (CVRM) together forms one of AstraZeneca's three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company's ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism (CVRM) and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Relations 
 Gonzalo Viña                                                                  +442037495916 
 Rob Skelding                           Oncology                                    +44 203 749 5821 
 Rebecca Einhorn                        Oncology                                    +1 301 5184122 
 Matt Kent                              BioPharmaceuticals                          +44 203 749 5906 
 Jennifer Hursit                        Other                                       +44 203 749 5762 
 Christina Malmberg Hägerstrand    Sweden                                      +46 8 552 53 106 
 Michele Meixell                        US                                          +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                                +44 203 749 5712 
 Henry Wheeler                          Oncology                                    +44 203 749 5797 
 Christer Gruvris                       BioPharmaceuticals (CV, metabolism)         +44 203 749 5711 
 Nick Stone                             BioPharmaceuticals (respiratory, renal)     +44 203 749 5716 
 Josie Afolabi                          Other medicines                             +44 203 749 5631 
 Craig Marks                            Finance, fixed income                       +44 7881 615 764 
 Jennifer Kretzmann                     Corporate access, retail investors          +44 203 749 5824 
 US toll-free                                                                       +1 866 381 72 77 
 
 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCCKNDDPBKKACB

(END) Dow Jones Newswires

September 23, 2019 02:01 ET (06:01 GMT)

Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191210 05:56:03